Skip to search formSkip to main contentSkip to account menu

deleobuvir

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

AcrylatesBenzimidazoles

Narrower (1)

BI 207127

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes
The drug-drug interaction (DDI) potential of deleobuvir, an hepatitis C virus (HCV) polymerase inhibitor, and its two major… 
2016
2016
Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir
Background & Aim The resistance profile of anti-hepatitis C virus (HCV) agents used in combination is important to guide optimal… 
2016
2016
Open‐label phase 2 study of faldaprevir, deleobuvir and ribavirin in Japanese treatment‐naive patients with chronic hepatitis C virus genotype 1 infection
The safety and efficacy of the NS3/4A protease inhibitor faldaprevir in combination with the non‐nucleoside NS5B polymerase… 
2015
2015
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection
Background & Aim Whether inosine triphosphatase (ITPA) gene polymorphisms predict anemia during interferon-free therapy in… 
Review
2015
Review
2015
Faldaprevir for the Treatment of Hepatitis C
The current treatments for chronic hepatitis C virus (HCV) genotype 1 infection are combinations of direct-acting antivirals, and… 
2015
2015
Synthesis of deleobuvir, a potent hepatitis C virus polymerase inhibitor, and its major metabolites labeled with carbon-13 and carbon-14.
Deleobuvir, (2E)-3-(2-{1-[2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido]cyclobutyl}-1-methyl-1H… 
2015
2015
Metabolism and the Microbiome Defining the Role of Gut Bacteria in the Metabolism of Deleobuvir : In Vitro and In Vivo Studies
Deleobuvir is a potent inhibitor of the hepatitis C virus nonstructural protein 5B polymerase. In humans, deleobuvir underwent… 
2014
2014
Current race in the development of DAAs (direct-acting antivirals) against HCV.
2014
2014
A highly concise and convergent synthesis of HCV polymerase inhibitor Deleobuvir (BI 207127): application of a one-pot borylation-Suzuki coupling reaction.
A highly concise and convergent synthesis of HCV polymerase inhibitor Deleobuvir (BI 207127, 1) was achieved, featuring efficient… 
2013
2013
interferon-free Treatment with Faldaprevir, Deleobuvir (bi 207127) and Ribavirin in Sound-c3: 95% Svr12 in Hcv-gt1b : 1102
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)